The case for & against
Bull & Bear analysis
Bearish
WW International, Inc. (NASDAQ: WW), formerly known as Weight Watchers, is a leading company in the weight management and wellness sector. The organization integrates behavioral programs with clinical offerings, particularly focusing on the emerging GLP-1 medication market. By aligning its services with modern therapeutic trends, WW aims to cater to a diverse audience seeking effective weight health solutions, navigating the growing demand for integrated healthcare models.
Bull says
- ↑Clinical subscribers grew to 197k, up 51% sequentially.
- ↑Adjusted EBITDA margin at 34%, reflecting disciplined cost management.
- ↑2026 revenue guidance of $620–635M implies strong mid-teens growth.
- ↑Debt reduced by over 70%, freeing capital for new initiatives.
- ↑ARPU up 13% YoY to $20.59; clinical ARPU is over 4× behavioral.
- ↑Strong profitability factors and favorable liquidity underpin resilience.
Bear says
- ↓Behavioral subscribers fell 25% YoY to 2.5M, eroding revenue.
- ↓Revenue down 10% YoY to $168M on subscriber mix shift.
- ↓Cash down to $121M vs. $160M prior quarter; interest burden persists.
- ↓Integration challenges as behavioral member acquisition remains strained.
- ↓Negative earnings yield and weak growth factors signal investor caution.
- ↓Intense GLP-1 competition risks pricing pressure and subscriber losses.
Investment themes with WW
Consumer Services↑ +0.53%
Everyday goods and personal services for consumers
MAR · DASH · EBAY
Weight Loss↓ -0.36%
Products and services targeting weight management
LLY · NVO · VKTX
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-11-2026bullish
Transcript signals
Bull points
- We remain confident that this approach can help Weight Watchers create better health outcomes for our members while driving higher lifetime value and return the company to profitable long-term growth.
- Through the first three months of 2026, demand for GLT-1s has accelerated with the launch of oral versions.
- Our unique portfolio of weight health offerings enables members to choose the right level of support for wherever they are on their weight loss journey, with or without medications.
Bear points
- While end-of-period behavioral subscribers were 2.5 million at the end of Q1 2026, reflecting a 25% year-over-year decline,
- Revenue in Q1 was $168 million, down 10% year over year, reflecting the subscriber dynamics between our subscription tiers,
- the opening headwind for 2026 associated with our compounded semaglutide offering was approximately 20 million. And as a reminder, we stopped compounding in May of 2025 in accordance with the FDA guidelines. That did have a fairly large churn event in Q3 of 2025 last year. we were able to retain about 20% of those compounded semaglutide members across our ecosystem.
Read full transcript analysis ›